These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29536182)

  • 1. Paclitaxel and Erlotinib-co-loaded Solid Lipid Core Nanocapsules: Assessment of Physicochemical Characteristics and Cytotoxicity in Non-small Cell Lung Cancer.
    Gupta B; Poudel BK; Regmi S; Pathak S; Ruttala HB; Gautam M; An GJ; Jeong JH; Choi HG; Yong CS; Kim JO
    Pharm Res; 2018 Mar; 35(5):96. PubMed ID: 29536182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PEGylated polypeptide lipid nanocapsules to enhance the anticancer efficacy of erlotinib in non-small cell lung cancer.
    Kim J; Ramasamy T; Choi JY; Kim ST; Youn YS; Choi HG; Yong CS; Kim JO
    Colloids Surf B Biointerfaces; 2017 Feb; 150():393-401. PubMed ID: 27825759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-small cell lung cancer combination therapy: Hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab.
    Pang J; Xing H; Sun Y; Feng S; Wang S
    Biomed Pharmacother; 2020 May; 125():109861. PubMed ID: 32070872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fabrication and in vivo evaluation of ligand appended paclitaxel and artemether loaded lipid nanoparticulate systems for the treatment of NSCLC: A nanoparticle assisted combination oncotherapy.
    Khatri H; Chokshi N; Rawal S; Patel BM; Badanthadka M; Patel MM
    Int J Pharm; 2020 Jun; 583():119386. PubMed ID: 32376440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer.
    Mandal B; Mittal NK; Balabathula P; Thoma LA; Wood GC
    Eur J Pharm Sci; 2016 Jan; 81():162-71. PubMed ID: 26517962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erlotinib complexation with randomly methylated
    Erdoğar N; Akkın S; Varan G; Bilensoy E
    Pharm Dev Technol; 2021 Sep; 26(7):797-806. PubMed ID: 34219578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer.
    Lv S; Tang Z; Li M; Lin J; Song W; Liu H; Huang Y; Zhang Y; Chen X
    Biomaterials; 2014 Jul; 35(23):6118-29. PubMed ID: 24794923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
    He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
    Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of multifunctional lipid nanocapsules for the co-delivery of paclitaxel and CpG-ODN in the treatment of glioblastoma.
    Lollo G; Vincent M; Ullio-Gamboa G; Lemaire L; Franconi F; Couez D; Benoit JP
    Int J Pharm; 2015 Nov; 495(2):972-80. PubMed ID: 26428632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib-Loaded Poly(ε-Caprolactone) Nanocapsules Improve In Vitro Cytotoxicity and Anticlonogenic Effects on Human A549 Lung Cancer Cells.
    Bruinsmann FA; Buss JH; Souto GD; Schultze E; de Cristo Soares Alves A; Seixas FK; Collares TV; Pohlmann AR; Guterres SS
    AAPS PharmSciTech; 2020 Aug; 21(6):229. PubMed ID: 32778976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells.
    Patel K; Doddapaneni R; Patki M; Sekar V; Bagde A; Singh M
    AAPS PharmSciTech; 2019 Mar; 20(3):135. PubMed ID: 30830506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erlotinib entrapped in cholesterol-depleting cyclodextrin nanoparticles shows improved antitumoral efficacy in 3D spheroid tumors of the lung and the liver.
    Varan G; Akkın S; Demirtürk N; Benito JM; Bilensoy E
    J Drug Target; 2021 Apr; 29(4):439-453. PubMed ID: 33210947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PEGylated-Paclitaxel and Dihydroartemisinin Nanoparticles for Simultaneously Delivering Paclitaxel and Dihydroartemisinin to Colorectal Cancer.
    Phung CD; Le TG; Nguyen VH; Vu TT; Nguyen HQ; Kim JO; Yong CS; Nguyen CN
    Pharm Res; 2020 Jun; 37(7):129. PubMed ID: 32548664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
    Furugaki K; Fukumura J; Iwai T; Yorozu K; Kurasawa M; Yanagisawa M; Moriya Y; Yamamoto K; Suda K; Mizuuchi H; Mitsudomi T; Harada N
    Int J Cancer; 2016 Feb; 138(4):1024-32. PubMed ID: 26370161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy.
    Wang G; Wang Z; Li C; Duan G; Wang K; Li Q; Tao T
    Biomed Pharmacother; 2018 Oct; 106():275-284. PubMed ID: 29966971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced antitumor efficacy by paclitaxel-loaded pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance.
    Zhang W; Shi Y; Chen Y; Yu S; Hao J; Luo J; Sha X; Fang X
    Eur J Pharm Biopharm; 2010 Aug; 75(3):341-53. PubMed ID: 20451605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mannosylated solid lipid nanoparticles for lung-targeted delivery of Paclitaxel.
    Sahu PK; Mishra DK; Jain N; Rajoriya V; Jain AK
    Drug Dev Ind Pharm; 2015 Apr; 41(4):640-9. PubMed ID: 24564799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emodin enhances antitumor effect of paclitaxel on human non-small-cell lung cancer cells in vitro and in vivo.
    Chen S; Zhang Z; Zhang J
    Drug Des Devel Ther; 2019; 13():1145-1153. PubMed ID: 31114158
    [No Abstract]   [Full Text] [Related]  

  • 19. Nanotechnology Based Repositioning of an Anti-Viral Drug for Non-Small Cell Lung Cancer (NSCLC).
    Parvathaneni V; Goyal M; Kulkarni NS; Shukla SK; Gupta V
    Pharm Res; 2020 Jun; 37(7):123. PubMed ID: 32514688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
    Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Kirschbrown W; Holen KD; Rosen LS
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1025-32. PubMed ID: 26420235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.